Congratulations to Seattle Genetics for their US FDA Approval of TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for patients with metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimens. Tucatinib-based treatment improved overall and progression-free survival. A new targeted therapy, another reason to test breast cancer patients for HER2.

https://lnkd.in/es6hitM